Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Albemarle Corporation stock logo
ALB
Albemarle
$171.78
+0.1%
$182.70
$53.70
$221.00
$20.24B1.362.11 million shs1.68 million shs
Albemarle Corporation stock logo
ALB
Albemarle
$171.78
+0.1%
$182.70
$53.70
$221.00
$20.24B1.362.11 million shs1.68 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$46.88
$50.69
$22.28
$59.55
$18.60B1.058.07 million shs4.22 million shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Albemarle Corporation stock logo
ALB
Albemarle
0.00%-2.27%-8.68%-8.08%+198.03%
Albemarle Corporation stock logo
ALB
Albemarle
0.00%-2.27%-8.68%-8.08%+198.03%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-2.56%-7.59%-7.21%+78.52%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Albemarle Corporation stock logo
ALB
Albemarle
$171.78
+0.1%
$182.70
$53.70
$221.00
$20.24B1.362.11 million shs1.68 million shs
Albemarle Corporation stock logo
ALB
Albemarle
$171.78
+0.1%
$182.70
$53.70
$221.00
$20.24B1.362.11 million shs1.68 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$46.88
$50.69
$22.28
$59.55
$18.60B1.058.07 million shs4.22 million shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Albemarle Corporation stock logo
ALB
Albemarle
0.00%-2.27%-8.68%-8.08%+198.03%
Albemarle Corporation stock logo
ALB
Albemarle
0.00%-2.27%-8.68%-8.08%+198.03%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-2.56%-7.59%-7.21%+78.52%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Albemarle Corporation stock logo
ALB
Albemarle
2.54
Moderate Buy$200.2616.58% Upside
Albemarle Corporation stock logo
ALB
Albemarle
2.54
Moderate Buy$200.2616.58% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.84
Reduce$35.73-23.78% Downside

Current Analyst Ratings Breakdown

Latest ALB, MRNA, and ALB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2026
Albemarle Corporation stock logo
ALB
Albemarle
Boost Price TargetOutperform$200.00 ➝ $215.00
5/14/2026
Albemarle Corporation stock logo
ALB
Albemarle
Boost Price TargetOutperform$200.00 ➝ $215.00
5/13/2026
Albemarle Corporation stock logo
ALB
Albemarle
Boost Price TargetSector Outperform$200.00 ➝ $215.00
5/13/2026
Albemarle Corporation stock logo
ALB
Albemarle
Boost Price TargetSector Outperform$200.00 ➝ $215.00
5/12/2026
Albemarle Corporation stock logo
ALB
Albemarle
Boost Price TargetBuy$210.00 ➝ $250.00
5/12/2026
Albemarle Corporation stock logo
ALB
Albemarle
Boost Price TargetBuy$210.00 ➝ $250.00
5/11/2026
Albemarle Corporation stock logo
ALB
Albemarle
UpgradeHoldStrong-Buy
5/11/2026
Albemarle Corporation stock logo
ALB
Albemarle
Boost Price TargetOutperform$245.00 ➝ $253.00
5/11/2026
Albemarle Corporation stock logo
ALB
Albemarle
Boost Price TargetBuy$185.00 ➝ $230.00
5/11/2026
Albemarle Corporation stock logo
ALB
Albemarle
Boost Price Target$230.00 ➝ $244.00
5/11/2026
Albemarle Corporation stock logo
ALB
Albemarle
UpgradeHoldStrong-Buy
(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Albemarle Corporation stock logo
ALB
Albemarle
$5.14B3.94$6.36 per share27.03$66.76 per share2.57
Albemarle Corporation stock logo
ALB
Albemarle
$5.14B3.94$6.36 per share27.03$66.76 per share2.57
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B9.57N/AN/A$18.67 per share2.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Albemarle Corporation stock logo
ALB
Albemarle
-$510.63M-$3.41N/A13.760.86-5.00%5.22%2.51%7/29/2026 (Estimated)
Albemarle Corporation stock logo
ALB
Albemarle
-$510.63M-$3.41N/A13.760.86-5.00%5.22%2.51%7/29/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)

Latest ALB, MRNA, and ALB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
Albemarle Corporation stock logo
ALB
Albemarle
$1.24$2.95+$1.71$2.34$1.34 billion$1.43 billion
5/6/2026Q1 2026
Albemarle Corporation stock logo
ALB
Albemarle
$1.24$2.95+$1.71$2.34$1.34 billion$1.43 billion
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Albemarle Corporation stock logo
ALB
Albemarle
$1.620.94%+1.02%N/A 30 Years
Albemarle Corporation stock logo
ALB
Albemarle
$1.620.94%+1.02%N/A 30 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest ALB, MRNA, and ALB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2026
Albemarle Corporation stock logo
ALB
Albemarle
quarterly$0.40500.83%6/12/20266/12/20267/1/2026
5/5/2026
Albemarle Corporation stock logo
ALB
Albemarle
quarterly$0.40500.83%6/12/20266/12/20267/1/2026
2/26/2026
Albemarle Corporation stock logo
ALB
Albemarle
quarterly$0.40501.03%3/13/20263/13/20264/1/2026
2/26/2026
Albemarle Corporation stock logo
ALB
Albemarle
quarterly$0.40501.03%3/13/20263/13/20264/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Albemarle Corporation stock logo
ALB
Albemarle
0.23
2.07
1.21
Albemarle Corporation stock logo
ALB
Albemarle
0.23
2.07
1.21
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35

Institutional Ownership

CompanyInstitutional Ownership
Albemarle Corporation stock logo
ALB
Albemarle
92.87%
Albemarle Corporation stock logo
ALB
Albemarle
92.87%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Albemarle Corporation stock logo
ALB
Albemarle
0.42%
Albemarle Corporation stock logo
ALB
Albemarle
0.42%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Albemarle Corporation stock logo
ALB
Albemarle
7,800117.93 million117.44 millionOptionable
Albemarle Corporation stock logo
ALB
Albemarle
7,800117.93 million117.44 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable

Recent News About These Companies

Moderna’s mRNA flu shot to get FDA review
Noubar Afeyan Sells 9,263 Shares of Moderna (NASDAQ:MRNA) Stock
Moderna (NASDAQ:MRNA) Director Sells $433,878.92 in Stock
James Mock Joins Moderna as Chief Financial Officer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Albemarle stock logo

Albemarle NYSE:ALB

$171.78 +0.20 (+0.12%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$171.94 +0.16 (+0.09%)
As of 05/22/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Specialties segment provides bromine-based specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals; lithium specialties, such as butyllithium and lithium aluminum hydride; develops and manufactures cesium products for the chemical and pharmaceutical industries; and zirconium, barium, and titanium products for pyrotechnical applications that include airbag initiators. The Ketjen segment offers clean fuels technologies (CFT), which is composed of hydroprocessing catalysts (HPC) together with isomerization and akylation catalysts; fluidized catalytic cracking (FCC) catalysts and additives; and performance catalyst solutions (PCS), which is composed of organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, and crop protection markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.

Albemarle stock logo

Albemarle NYSE:ALB

$171.78 +0.20 (+0.12%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$171.94 +0.16 (+0.09%)
As of 05/22/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Specialties segment provides bromine-based specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals; lithium specialties, such as butyllithium and lithium aluminum hydride; develops and manufactures cesium products for the chemical and pharmaceutical industries; and zirconium, barium, and titanium products for pyrotechnical applications that include airbag initiators. The Ketjen segment offers clean fuels technologies (CFT), which is composed of hydroprocessing catalysts (HPC) together with isomerization and akylation catalysts; fluidized catalytic cracking (FCC) catalysts and additives; and performance catalyst solutions (PCS), which is composed of organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, and crop protection markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.

Moderna stock logo

Moderna NASDAQ:MRNA

$46.88 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$46.89 +0.01 (+0.02%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.